Corrigendum to “PTGER3 induces ovary tumorigenesis and confers resistance to cisplatin therapy through up-regulation Ras-MAPK/Erk-ETS1-ELK1/CFTR1 axis” [EBioMedicine 40 (2019) 290-304, (EBioMedicine (2019) 40(290-304) (S2352396418305498), (10.1016/j.ebiom.2018.11.045))

Cristian Rodriguez-Aguayo; Emine Bayraktar; Cristina Ivan; Burcu Aslan; Junhua Mai; Guangan He; Lingegowda S. Mangala; Dahai Jiang; Archana S. Nagaraja; Bulent Ozpolat; Arturo Chavez-Reyes; Mauro Ferrari; Rahul Mitra; Zahid H. Siddik; Haifa Shen; Xianbin Yang; Anil K. Sood; Gabriel Lopez-Berestein

doi:10.1016/j.ebiom.2022.104194

Corrigendum to “PTGER3 induces ovary tumorigenesis and confers resistance to cisplatin therapy through up-regulation Ras-MAPK/Erk-ETS1-ELK1/CFTR1 axis” [EBioMedicine 40 (2019) 290-304, (EBioMedicine (2019) 40(290-304) (S2352396418305498), (10.1016/j.ebiom.2018.11.045))

Cristian Rodriguez-Aguayo, Emine Bayraktar, Cristina Ivan, Burcu Aslan, Junhua Mai, Guangan He, Lingegowda S. Mangala, Dahai Jiang, Archana S. Nagaraja, Bulent Ozpolat, Arturo Chavez-Reyes, Mauro Ferrari, Rahul Mitra, Zahid H. Siddik, Haifa Shen, Xianbin Yang, Anil K. Sood, Gabriel Lopez-Berestein

Research output: Contribution to journal › Comment/debate › peer-review

Abstract

The authors noticed that in Figure 6B, the TUNEL staining panel for the “PTGER3 siRNA” group was inadvertently duplicated in the next position for the group of “2’F-PS2-PTGER3 siRNA”. Below is the corrected version of Figure 6B TUNEL staining panels with a new representative image for the 2’F-PS2-PTGER3 siRNA group. This change does not affect the results or conclusions. The authors apologize for any inconvenience caused.

Original language	English (US)
Article number	104194
Journal	EBioMedicine
Volume	83
DOIs	https://doi.org/10.1016/j.ebiom.2022.104194
State	Published - Sep 2022

ASJC Scopus subject areas

General Biochemistry, Genetics and Molecular Biology

Access to Document

10.1016/j.ebiom.2022.104194

Fingerprint

Dive into the research topics of 'Corrigendum to “PTGER3 induces ovary tumorigenesis and confers resistance to cisplatin therapy through up-regulation Ras-MAPK/Erk-ETS1-ELK1/CFTR1 axis” [EBioMedicine 40 (2019) 290-304, (EBioMedicine (2019) 40(290-304) (S2352396418305498), (10.1016/j.ebiom.2018.11.045))'. Together they form a unique fingerprint.

Cite this

Rodriguez-Aguayo, C., Bayraktar, E., Ivan, C., Aslan, B., Mai, J., He, G., Mangala, L. S., Jiang, D., Nagaraja, A. S., Ozpolat, B., Chavez-Reyes, A., Ferrari, M., Mitra, R., Siddik, Z. H., Shen, H., Yang, X., Sood, A. K., & Lopez-Berestein, G. (2022). Corrigendum to “PTGER3 induces ovary tumorigenesis and confers resistance to cisplatin therapy through up-regulation Ras-MAPK/Erk-ETS1-ELK1/CFTR1 axis” [EBioMedicine 40 (2019) 290-304, (EBioMedicine (2019) 40(290-304) (S2352396418305498), (10.1016/j.ebiom.2018.11.045)). EBioMedicine, 83, Article 104194. https://doi.org/10.1016/j.ebiom.2022.104194

Corrigendum to “PTGER3 induces ovary tumorigenesis and confers resistance to cisplatin therapy through up-regulation Ras-MAPK/Erk-ETS1-ELK1/CFTR1 axis” [EBioMedicine 40 (2019) 290-304, (EBioMedicine (2019) 40(290-304) (S2352396418305498), (10.1016/j.ebiom.2018.11.045)). / Rodriguez-Aguayo, Cristian; Bayraktar, Emine; Ivan, Cristina et al.
In: EBioMedicine, Vol. 83, 104194, 09.2022.

Research output: Contribution to journal › Comment/debate › peer-review

Rodriguez-Aguayo, C, Bayraktar, E, Ivan, C, Aslan, B, Mai, J, He, G , Mangala, LS, Jiang, D, Nagaraja, AS, Ozpolat, B, Chavez-Reyes, A, Ferrari, M, Mitra, R, Siddik, ZH, Shen, H, Yang, X, Sood, AK & Lopez-Berestein, G 2022, 'Corrigendum to “PTGER3 induces ovary tumorigenesis and confers resistance to cisplatin therapy through up-regulation Ras-MAPK/Erk-ETS1-ELK1/CFTR1 axis” [EBioMedicine 40 (2019) 290-304, (EBioMedicine (2019) 40(290-304) (S2352396418305498), (10.1016/j.ebiom.2018.11.045))', EBioMedicine, vol. 83, 104194. https://doi.org/10.1016/j.ebiom.2022.104194

Rodriguez-Aguayo C, Bayraktar E, Ivan C, Aslan B, Mai J, He G et al. Corrigendum to “PTGER3 induces ovary tumorigenesis and confers resistance to cisplatin therapy through up-regulation Ras-MAPK/Erk-ETS1-ELK1/CFTR1 axis” [EBioMedicine 40 (2019) 290-304, (EBioMedicine (2019) 40(290-304) (S2352396418305498), (10.1016/j.ebiom.2018.11.045)). EBioMedicine. 2022 Sep;83:104194. doi: 10.1016/j.ebiom.2022.104194

Rodriguez-Aguayo, Cristian ; Bayraktar, Emine ; Ivan, Cristina et al. / Corrigendum to “PTGER3 induces ovary tumorigenesis and confers resistance to cisplatin therapy through up-regulation Ras-MAPK/Erk-ETS1-ELK1/CFTR1 axis” [EBioMedicine 40 (2019) 290-304, (EBioMedicine (2019) 40(290-304) (S2352396418305498), (10.1016/j.ebiom.2018.11.045)). In: EBioMedicine. 2022 ; Vol. 83.

@article{ee06297ad06047afb1efc85dc9477c8d,

title = "Corrigendum to “PTGER3 induces ovary tumorigenesis and confers resistance to cisplatin therapy through up-regulation Ras-MAPK/Erk-ETS1-ELK1/CFTR1 axis” [EBioMedicine 40 (2019) 290-304, (EBioMedicine (2019) 40(290-304) (S2352396418305498), (10.1016/j.ebiom.2018.11.045))",

abstract = "The authors noticed that in Figure 6B, the TUNEL staining panel for the “PTGER3 siRNA” group was inadvertently duplicated in the next position for the group of “2{\textquoteright}F-PS2-PTGER3 siRNA”. Below is the corrected version of Figure 6B TUNEL staining panels with a new representative image for the 2{\textquoteright}F-PS2-PTGER3 siRNA group. This change does not affect the results or conclusions. The authors apologize for any inconvenience caused.",

author = "Cristian Rodriguez-Aguayo and Emine Bayraktar and Cristina Ivan and Burcu Aslan and Junhua Mai and Guangan He and Mangala, {Lingegowda S.} and Dahai Jiang and Nagaraja, {Archana S.} and Bulent Ozpolat and Arturo Chavez-Reyes and Mauro Ferrari and Rahul Mitra and Siddik, {Zahid H.} and Haifa Shen and Xianbin Yang and Sood, {Anil K.} and Gabriel Lopez-Berestein",

note = "Publisher Copyright: {\textcopyright} 2022",

year = "2022",

month = sep,

doi = "10.1016/j.ebiom.2022.104194",

language = "English (US)",

volume = "83",

journal = "EBioMedicine",

issn = "2352-3964",

publisher = "Elsevier BV",

}

TY - JOUR

T1 - Corrigendum to “PTGER3 induces ovary tumorigenesis and confers resistance to cisplatin therapy through up-regulation Ras-MAPK/Erk-ETS1-ELK1/CFTR1 axis” [EBioMedicine 40 (2019) 290-304, (EBioMedicine (2019) 40(290-304) (S2352396418305498), (10.1016/j.ebiom.2018.11.045))

AU - Rodriguez-Aguayo, Cristian

AU - Bayraktar, Emine

AU - Ivan, Cristina

AU - Aslan, Burcu

AU - Mai, Junhua

AU - He, Guangan

AU - Mangala, Lingegowda S.

AU - Jiang, Dahai

AU - Nagaraja, Archana S.

AU - Ozpolat, Bulent

AU - Chavez-Reyes, Arturo

AU - Ferrari, Mauro

AU - Mitra, Rahul

AU - Siddik, Zahid H.

AU - Shen, Haifa

AU - Yang, Xianbin

AU - Sood, Anil K.

AU - Lopez-Berestein, Gabriel

PY - 2022/9

Y1 - 2022/9

N2 - The authors noticed that in Figure 6B, the TUNEL staining panel for the “PTGER3 siRNA” group was inadvertently duplicated in the next position for the group of “2’F-PS2-PTGER3 siRNA”. Below is the corrected version of Figure 6B TUNEL staining panels with a new representative image for the 2’F-PS2-PTGER3 siRNA group. This change does not affect the results or conclusions. The authors apologize for any inconvenience caused.

AB - The authors noticed that in Figure 6B, the TUNEL staining panel for the “PTGER3 siRNA” group was inadvertently duplicated in the next position for the group of “2’F-PS2-PTGER3 siRNA”. Below is the corrected version of Figure 6B TUNEL staining panels with a new representative image for the 2’F-PS2-PTGER3 siRNA group. This change does not affect the results or conclusions. The authors apologize for any inconvenience caused.

UR - http://www.scopus.com/inward/record.url?scp=85135114960&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85135114960&partnerID=8YFLogxK

U2 - 10.1016/j.ebiom.2022.104194

DO - 10.1016/j.ebiom.2022.104194

M3 - Comment/debate

C2 - 35914489

AN - SCOPUS:85135114960

SN - 2352-3964

VL - 83

JO - EBioMedicine

JF - EBioMedicine

M1 - 104194

ER -

Corrigendum to “PTGER3 induces ovary tumorigenesis and confers resistance to cisplatin therapy through up-regulation Ras-MAPK/Erk-ETS1-ELK1/CFTR1 axis” [EBioMedicine 40 (2019) 290-304, (EBioMedicine (2019) 40(290-304) (S2352396418305498), (10.1016/j.ebiom.2018.11.045))

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this